Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.92 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.70 +9.1% TUNG 1.74 +3.0% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
Management Routine +

COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO

SEC deregistration cleared, permanent CEO installed, but cash runway remains tight.

By The Northwire Desk — AI Analysis Jun 18, 2026 · 08:30 CSCI · 3.24 COSCIENS BIOPHARMA INC
Executive Summary
  • Shareholders approved all proposals at the annual general and special meeting, including director re-elections and auditor re-appointment.
  • The approved corporate share capital amendment authorizes a 150-for-1 share consolidation followed immediately by a 50-for-1 share split.
  • Peter H. Puccetti has been appointed as the permanent, full-time President and CEO, transitioning from his interim tenure that began in November 2025.
  • No new financial results, guidance, or operational updates were provided in this release.
Material Impact
  • The news is Routine - Positive. The shareholder approval of the share consolidation/split and the permanent CEO appointment were fully telegraphed and expected. The +22.7% run-up into the print indicates the market had already priced in the successful deregistration and leadership continuity. The underlying facts do not change the fundamental trajectory: a leaner, non-SEC reporting company with a tight cash balance and a shrinking core business. The market reaction and underlying facts are aligned; there is no new alpha here.
CSCI · Price
Company Overview
  • COSCIENS Biopharma Inc. develops natural plant-based active ingredients and commercializes pharmaceutical/diagnostic products. It recently discontinued its German subsidiaries and the AvenActive program, pivoting to a leaner focus on active ingredients and exploring strategic opportunities. The company is transitioning to OTCQB trading and suspending SEC reporting to reduce compliance overhead.
Read the original news release →

More from COSCIENS BIOPHARMA INC

May 12, 2026 · 17:05

COSCIENS Posts Accounting Profit Amidst Cash Burn and Program Cuts

Earnings Apr 20, 2026 · 08:00

COSCIENS Biopharma Proposes Share Consolidation to Cut Reporting Costs and Exit U.S. Registry

Other Mar 25, 2026 · 17:05

COSCIENS Sheds German Subsidiaries and $11M Pension Liability as Cash Burn Outpaces Declining Revenue

Earnings Mar 05, 2026 · 17:10

COSCIENS Provides Strategic Update

Other Dec 01, 2025 · 17:05

COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen(TM) in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore

M&A / Property Nov 14, 2025 · 17:15

COSCIENS Biopharma Inc. Announces Leadership Change

Management